The combination of thiamidol, tretinoin and a corticosteroid is a variant of the traditional triple combination therapy, with thiamidol taking the place of hydroquinone as the depigmenting agent. It was evaluated in a clinical trial in 2023 as an alternative treatment option for melasma, where the results showed that it was at least as effective as the standard triple combination cream, and had potentially milder side effects (R).
| Outcome | Effect | Frequency | Studies | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peeling | ⇧ Increase |
|
||||||||
| Skin Redness | ⇧ Increase |
|
||||||||
| Irritation | ⇧ Increase |
|
||||||||
| Acne | ⇧ Increase | — | ||||||||
| Skin Hydration | ⇩ Decrease | — | ||||||||